In Brief
Serrated adenocarcinomas are an aggressive and treatment-resistant form of colorectal cancer. Nakanishi et al. show that expression of atypical PKCs is reduced in human serrated tumors and that their loss results in spontaneous serrated tumorigenesis with stromal activation and immunosuppression in mice. The simultaneous inhibition of stromal activation combined with anti-PD-L1 showed synergistic therapeutic potential.
INTRODUCTION
Colorectal cancer (CRC) develops through precursor lesions that originate from either ''conventional'' or ''alternative'' pathways (IJspeert et al., 2015) . The conventional pathway is predominately initiated by the inactivation of the Apc tumor-suppressor gene and results in a tubular adenoma histology (Fearon and Vogelstein, 1990) . The alternative pathway is initiated by the formation of ''serrated'' adenoma in the absence of changes in APC or b-catenin and is associated with activation of the ERK cascade, occasionally as a result of activating mutations in KRAS or BRAF (IJspeert et al., 2015) . Although undoubtedly important, these mutations are not present in all serrated adenomas (IJspeert et al., 2015) . Moreover, in mouse models, the additional inactivation of tumor suppressors, such as p16 INK4a , p53, or CDX2, outside of the ERK pathway is required for these tumors to progress to the advanced carcinoma stage (Bennecke et al., 2010; Rad et al., 2013) . Despite these important observations, little is known about the role of the tumor microenvironment in the development of serrated CRC. There is no clear therapeutic consensus on how, or whether, CRC originating from the serrated pathway should be treated differently than conventional CRC. Recent studies have demonstrated that serrated precursor lesions are associated with a transcriptional CRC subtype that has a very poor prognosis (De Sousa E. Melo et al., 2013) . Encouragingly, emerging evidence suggests that immunotherapy could be a viable option for patients with serrated CRC, specifically those of the microsatellite instability (MSI)-high or mismatch-repair-deficient (dMMR) type (Le et al., 2015) . Although the MSI-high phenotype is associated with serrated tumorigenesis, a significant proportion of poor-prognosis serrated tumors are microsatellite stable (MSS) and respond poorly to single-agent PD-1 inhibitor treatment, yet a subgroup of MSS patients have high PD-1 expression and have been suggested to benefit from checkpoint T cell therapies (Mlecnik et al., 2016) . Understanding the immunological environment of serrated tumors is critically important for identifying more efficacious therapies. Because immunosuppression and inflammation might play key roles in the development of serrated CRCs, a detailed mechanistic study on the potential function of immunity in serrated tumor initiation and progression is of paramount importance for prevention and treatment.
Intestinal chronic inflammatory diseases are associated with elevated risk of CRC (Beaugerie and Itzkowitz, 2015) . We recently identified atypical protein kinase C (aPKC) l/i (PKCl/i; encoded by PRKCI) as a regulator of intestinal inflammation in the context of inflammatory bowel diseases (IBDs), such as Crohn's disease (CD) and ulcerative colitis (UC) (Nakanishi et al., 2016) . PKCl/i is required for Paneth cell differentiation and is a negative regulator of cell death in the intestinal epithelium (Nakanishi et al., 2016) . PKCl/i amounts decrease in Paneth cells of CD patients in a manner that correlates with disease progression (Nakanishi et al., 2016) . Furthermore, a Kaplan-Meier survival analysis of CRC patients demonstrated that low PKCl/i amounts correlate with significantly worse patient survival rates (Nakanishi et al., 2016) . This proinflammatory environment of the PKCl/i-deficient intestinal epithelium is most likely linked to a defective barrier caused by impaired Paneth cell differentiation and increased intestinal epithelial cell (IEC) death (Nakanishi et al., 2016) . However, even in the presence of chronic inflammation, the selective genetic inactivation of PKCl/i in the intestinal epithelium does not lead to tumorigenesis unless combined with Apc deficiency, in which case the number of intestinal adenomas increases significantly through a mechanism that depends on inflammation and the microbiome; however, these adenomas never progress to aggressive or invasive stages (Nakanishi et al., 2016) . One potential explanation is that the other aPKC, PKCz (encoded by the gene PRKCZ), might maintain pathways that can prevent cancer initiation and progression in PKCl/i-deficient intestines. Here, we explore the mechanisms of serrated tumor initiation in the context of the simultaneous genetic inactivation of both aPKCs, their relevance in human serrated CRC, and the potential implications for therapy. We demonstrate that PKCl/i and PKCz provide complementary and unique functions that cooperate to suppress intestinal serrated tumorigenesis. Villin-cre mice were born at the expected Mendelian ratios but showed reduced body size and weight, as well as a worse survival rate than wild-type (WT) mice ( Figures 1A-1C) . Villin-cre intestines often appeared dilated and full, suggesting altered intestinal function and obstruction (Figure 1A) , and had a severe reduction in the number of Paneth cells in the crypts, as determined by lysozyme immunohistochemistry (IHC) ( Figure S1A ). Remaining Paneth cells were mislocalized at the upper crypt and villi, and a population of immature differentiated cells that stained positive for markers of both Paneth cells (lysozyme) and goblet cells (Alcian blue) was also found ( Figure S1A ). In both the small intestine and colon, Prkci Villin-cre mice exhibited a deformed, ''saw-tooth'' hyperplastic appearance, which resembled the human serrated phenotype ( Figure 1D ). This resemblance extended to the existence in the Prkci
RESULTS

Loss of Both aPKCs Results in Serrated Tumor
Villin-cre intestines of cytomorphologic features that were similar to human microvesicular or goblet-cell-rich serrated hyperplasia ( Figure S1B ), which is a premalignant lesion that can progress to CRC through an alternative pathway to the conventional ''adenoma-carcinoma'' sequence (IJspeert et al., 2015) . After 7 weeks of age, both the small intestines and colons of Prkci Villin-cre mice showed efficient and progressive development of intestinal tumors, which increased as the mice aged ( Figures 1F and S1C) . Although no significant differences were found in tumor distribution among distinct regions of the small intestine, there was a preference for the proximal location in the colon ( Figures 1G, 1H , and S1D), which closely mirrors the behavior of human serrated CRC. Colon tumors were occasionally accompanied by mucin inclusions ( Figure 1H ). Aberrant crypt formation in the form of lateral budding of crypts and cytological atypia was also observed, indicating the presence of accompanying dysplastic changes ( Figure 1D ). Furthermore, a large subset of Prkci
Villin-cre intestinal tumors progressed to intramucosal ( Figure 1D ) and even invasive adenocarcinoma ( Figure 1I ). That is, 72.2% (13/18) and 81.3% (13/16) of mice developed adenocarcinoma in the small intestine and colon, respectively.
Invasive adenocarcinoma includes not only a tubular adenocarcinoma component but also poorly differentiated carcinoma ( Figure 1J ) or signet-ring cell carcinoma, which is morphologically characterized by abundant intracytoplasmic mucin that pushes the nucleus to the periphery as indicated by Ki67 + Alcian blue + cells ( Figure 1K ). We also observed a severe desmoplastic change indicating the highly aggressive nature of those tumors ( Figure 1L ). Considering that poorly differentiated mucinous and signet-ring cell appearances have been associated with the MSS and aggressive phenotypes of human serrated tumors, this strongly suggests that and S1F). We did not observe changes in the mRNA expression of representative DNA-MMR genes in these tumors ( Figure S1G ). In agreement with the positive association between MSS;MSI-L and CpG island methylator phenotype (CIMP) low CIMP À profiles in human serrated tumors, none of the markers defining CIMP were altered ( Figure S1H ). Furthermore, senescence was not detected in Prkci fl/fl Prkcz fl/fl Villin-cre mouse intestines ( Figure S1I ). This is similar to what has been reported in serrated tumors driven by KRAS or BRAF (Bennecke et al., 2010; Rad et al., 2013) . Consistent with the notion that SSA/Ps are premalignant lesions, they showed increased expression of p53, p21, and p16, all of which reverted when the tumors reached the carcinoma stage ( Figure S1J ). These results demonstrate that the simultaneous loss of PKCl/i and PKCz in the intestinal epithelium leads to the development of SSA/Ps that further progress to MSS invasive carcinomas with a highly desmoplastic aggressive phenotype.
ERK, but Not Wnt-b-catenin, Signaling Is Activated in Prkci fl/fl Prkcz fl/fl Villin-cre Intestinal Epithelium CRC generated through the serrated pathway differs from the conventional adenoma-carcinoma phenotype also from the Villin-cre intestines. Red arrows denote invasive tumor front. Scale bars, 100 mm. Data are representative of or combined from ten independent experiments including male and female mice. Results are shown as mean ± SEM. ***p < 0.001, ****p < 0.0001. See also Figure S1 . (legend continued on next page) signaling and genetic point of view. The genetic differences are characterized by mutations in the Wnt-b-catenin signaling pathway and are much less frequent in serrated polyps (Fearon and Vogelstein, 1990 Figure 2D ). Targeted genome sequencing did not identify any alterations in potential coding hotspots for mutations in murine Braf (B637E) and Kras (G12D, G12V, and G13D) (data not shown). This strongly suggests that the simultaneous inactivation of both aPKCs activates the ERK pathway independently of genetic alterations in Braf or Kras. Gene-set enrichment analysis (GSEA) also revealed activation of the YAP pathway ( Figure 2E ), which was confirmed by IHC ( Figure 2D ). This could explain the activation of the ERK and EGFR pathways because YAP has been shown to control the expression of several EGF family members (Gregorieff et al., 2015) . The comparison of these transcriptomic data to recently reported gene signatures generated from human organoids from serrated lesions, tubular or tubulovillous adenoma, and MSI or MSS CRCs (Fujii et al., 2016) The combined loss of both aPKCs in IECs promoted a synergistic increase in cell proliferation that correlated with the spontaneous generation of serrated tumors ( Figure S2A ). Intestinal Inflammation Drives Serrated Tumorigenesis Treatment of Prkci fl/fl Prkcz fl/fl Villin-cre mice with a combination of broad-spectrum antibiotics, which abolish intestinal inflammation and the immune response (Nakanishi et al., 2016) , decreased the infiltration of CD45 + cells ( Figures 4A-4C ). This treatment also significantly abrogated tumorigenesis ( Figures  4D and 4E ). Therefore, although serrated tumorigenesis depends on an (Nakanishi et al., 2016) , which might initiate a CD8 + T cell response linked to immunogenic cell death (ICD) (Galluzzi et al., 2017) . The RNA sequencing (RNA-seq) data demonstrated the upregulation of several danger signals that confirm the ICD response ( Figure 5A ), along with ATP secretion ( Figure 5B ). In keeping with these data, PKCl/i-deficient cells from mouse intestinal epithelial cell line MODE-K showed increased apoptosis in response to several ICD stimuli ( Figures 5C and S5A ), suggesting that IECs are more prone to undergoing ICD in the absence of PKCl/i. The interferon pathway is also a critical cascade responsible for CD8 + T-cell-mediated anti-tumor immunity (Parker et al., 2016) . MODE-K cells deficient in PKCl/i showed a stronger induction of interferon-related transcripts, including of Cxcl10 (an essential chemokine for CD8 + recruitment), than the sgC control cells. ( Figure 5D ). Because the interferon response regulates antigen presentation, we next analyzed the expression of major histocompatibility complex (MHC) class I proteins by flow cytometry. Loss of PKCl/i significantly increased the expression of both H-2Kk and H-2Dk heavy chains at the surface of MODE-K cells ( Figure 5E ). All these data point to a higher CD8 + T cell response in the absence of PKCl/i than in its presence. To strengthen these results, we performed a CD8 + T-cell-mediated cytotoxicity assay by using MC38 cells expressing the model antigen ovalbumin (OVA) as target cells and CD8 + T cells isolated from OT-I mice as specific effector cells. The lack of PKCl/i in MC38 cells significantly increased the OT-I cell-mediated killing ( Figure 5F ), demonstrating that the loss of PKCl/i in intestinal epithelial cells promotes the CD8 + T cell response. Villin-cre IECs ( Figures 5H and S5D ). These data establish that the loss of PKCz contributes to serrated tumorigenesis by suppressing the interferon cellular response in a cell-autonomous manner. To further strengthen this conclusion, we carried out a series of ex vivo experiments by using 3D cultures of WT or Prkcz À/À organoids. DNA methyltransferase inhibitors (DNMTi) have recently been used to transcriptionally upregulate human endogenous activators of the double-stranded RNA sensing pathway that culminates in the stimulation of the type I and III interferon responses (Chiappinelli et al., 2015) . We incubated both types of organoids with the DNMTi 5-aza-2-deoxycytidine (5-AZA-CdR) for 24 hr and then subjected them to cell culture in the absence of this drug. 5-AZA-CdR treatment robustly induced the expression of To therapeutically exploit the increased infiltration of Prkci fl/fl Prkcz fl/fl Villin-cre tumors by PD-L1 + ;CD45 + cells, we treated these mice with an anti-PD-L1 for 3 weeks, starting at 10 weeks of age ( Figure S6A ). This treatment resulted in a robust reduction of the number, average size, and total load of tumors, as well as cancer incidence, which correlated with a concomitant increase in the recruitment of CD8 + cells into the tumor areas ( Figures S6B-S6D ). However, anti-PD-L1 treatment did not show any therapeutic effect when mice were treated from 13 weeks of age ( Figure S6E ), at which point they presented with a more advanced tumor burden and increased tumor aggressiveness ( Figures S6F-S6H ). Thus, once serrated tumors are established and are more aggressive, they become resistant to anti-PD-L1 therapy. One of the characteristics of the advanced Prkci fl/fl Prkcz fl/fl Villin-cre tumors is a high desmoplastic response, which has been proposed to be critical for CRC progression toward high malignancy (Calon et al., 2015; Isella et al., 2015) . Tumors from 16-week-old Prkci fl/fl Prkcz fl/fl Villin-cre mice showed higher expression of aSMA and collagen deposition than tumors from 13-week-old mice ( Figure S6I ), suggesting the potential contribution of an activated stroma to the resistance of these mice to therapy. We next tested whether the strong stromal response of serrated Prkci fl/fl Prkcz fl/fl Villin-cre tumors might be central to progression and the acquisition of a more aggressive phenotype. Because stromal activation in CRC relies on TGF-b signaling (Calon et al., 2015) , we treated 10-week-old Prkci fl/fl Prkcz fl/fl Villin-cre mice with the TGF-bR1-specific inhibitor galunisertib (LY2157299) ( Figure 6A ). Although this treatment did not reduce the tumor number, size, or load ( Figure 6B) , it suppressed the progression of SSA/Ps to the adenocarcinoma stage and especially reduced the incidence of invasive cancer (Figures 6C and 6D) . Consistent with the well-established role of TGF-b in stromal activation, treatment with galunisertib resulted in the inhibition of stromal phospho-SMAD2 and collagen deposition ( Figure 6D ), as well as in the reduced expression of TGFb-responsive genes, such as Angptl2, Cdkn2b, Il11, and Ereg ( Figure 6E) . Flow-cytometric analyses demonstrated a reduction in the proportion of Th17 cells in the tumors upon this treatment ( Figure 6F ), which is consistent with the crucial role of TGF-b in Th17 cell differentiation (Mangan et al., 2006) . However, this treatment did not significantly change the proportions of CD8 concomitant increase in CD8 + T cell infiltration into the tumors ( Figures 6P and 6Q) . However, there were no changes in the proportion of Treg cells, although there was a significant reduction of CD11b + myeloid cells ( Figures 6R and 6S ). These results demonstrate that, although anti-PD-L1 therapy is not effective in more advanced and desmoplastic serrated cancers, these are rendered sensitive to anti-PD-L1 treatment when the progression of SSA/P to adenocarcinoma is blunted by suppressing TGF-b signaling.
Human Serrated Tumors Display Reduced Expression of aPKCs
To establish the relevance of the aPKC loss in human serrated tumors, we first analyzed polyps that were pathologically classified as SSA/Ps or tubular adenomas (TAs). SSA/Ps are considered to be the epithelial precursor lesions that will progress toward serrated CRC, whereas TAs follow the conventional CRC pathway (De Sousa E. Melo et al., 2013; Fearon and Vogelstein, 1990 ). We used an antibody that recognizes both aPKCs ( Figure S7A ) to immunostain 30 SSA/P and 30 TA samples, along with 20 controls from healthy individuals. The aPKC amounts were significantly reduced in SSA/Ps but not in TA samples (Figures 7A and 7B) , which established the relevance of the aPKC loss in human serrated tumors. We next investigated whether low amounts of both aPKCs correlate with serrated features in CRC samples by using bioinformatics to interrogate the large dataset from patients with colorectal adenocarcinoma in The Cancer Genome Atlas (TCGA). Because these CRC samples are genetically and morphologically heterogeneous and are not annotated for their precursor origin through the serrated or conventional pathway, we first stratified patients on the basis of aPKC expression and performed GSEA with serrated or traditional adenoma gene signatures. Figure 7C ). Next, we attempted to classify CRC patients on the basis of molecular profiles. Although there have been multiple recent efforts to define different CRC molecular subtypes on the basis of gene expression, we focused on the CCS (colon cancer subtype) classification because this is the only one in which a subtype of tumors is clearly identified as having developed from serrated precursor lesions (De Sousa E. Melo et al., 2013) . This classification includes three subgroups: CCS1 represents chromosomal unstable, CCS2 is MSI;CIMP + , and CCS3 is largely MSS and relates to serrated tumors, including those with upregulation of stromal and EMT genes, and defines a subset of patients with the worst survival rates (De Sousa E. Melo et al., 2013) . The mRNA expression of both aPKCs were significantly reduced in the CCS3 subtype ( Figures 7D, S7B, and S7C) . Also, samples stratified by the expression of both aPKCs showed a marked segregation of patients by CCS classification. Figures 7F and S7F ), in keeping with the unfavorable prognosis associated with CCS3 patients. Stratification of TCGA patients according to their aPKC amounts also validated the critical role of these kinases in the negative regulation of the EMT and of the KRAS and YAP pathways, as well as in TGF-b signaling activation ( Figure 7G ). Furthermore, analysis of CRC patients according to their KRAS or BRAF mutational status revealed the existence of a PRKCI low PRKCZ low subset that was also WT for BRAF and KRAS ( Figure S7G ). GSEA of the transcriptomes of these patients showed a positive correlation with upregulated serrated and downregulated adenoma signatures and a positive enrichment in EMT and inflammatory signatures ( Figure S7H) Figures S7I and S7J ). These results demonstrate that the simultaneous loss of both aPKCs in human CRCs generates a phenotype in addition to that of the serrated KRAS-or Data represent the mean ± SEM of three to eight individual male mice per group for one experiment per treatment. *p < 0.05, **p < 0.01. See also Figure S6 . Results are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S7 .
BRAF-mutant
patients as compared with healthy individuals ( Figure 7H Figures 7I and 7J ). These results strongly support the notion that chronic inflammation is critical for the development of CRC through the serrated pathway and that the loss of aPKC is a central event in that process through the development of an immunosuppressive phenotype.
DISCUSSION
We demonstrated here that the simultaneous deletion of PKCz and PKCl/i in the mouse intestinal epithelium results in the development of SSA/Ps that progress to advanced cancer with a strongly reactive and immunosuppressive stroma. We also found that human intestinal serrated tumors express low amounts of PKCz and PKCl/i, and we established a strong correlation between reduced expression of both aPKCs and the mesenchymal and immunosuppressive phenotypes of human CRCs, which also display poor prognosis. These findings shed light on the unique functions of the individual aPKCs in cooperatively suppressing intestinal serrated tumorigenesis, specifically of the subtype with poor prognosis and highly aggressive stroma and mesenchyme. Our study provides mechanistic insights into the development of serrated tumorigenesis that occurs independently of KRAS or BRAF mutation and highlights that the stromal and inflammatory response induced by aPKC deficiency confers aggressive and therapy-resistant phenotypes to serrated lesions irrespectively of the KRAS or BRAF mutation status. This immunosuppressive environment constitutes a vulnerability of aPKC-deficient serrated tumors, and we have shown that it can be exploited therapeutically.
Prkci fl/fl Prkcz fl/fl Villin-cre mice exhibit an MSS profile, whereas the expression of mutant BRAF in the mouse intestinal epithelium results in MSI-H tumors (Rad et al., 2013) , and that of mutant KRAS gives an MSI-L;MSS phenotype (Bennecke et al., 2010 Villin-cre tumors are fully fledged adenocarcinomas, anti-PD-L1 therapy will benefit only from co-treatment with a TGF-b receptor inhibitor. Our results are reminiscent of data in a mouse model of liver metastasis induced by organoids from a quadruple mutant (Apc;Kras;Tgfbr2;Trp53) mouse model that mimics conventional CRC (Tauriello et al., 2018) , in which targeting TGF-b was critical for therapy. However, there are also substantial differences between the two models. Whereas non-overtly estab- These results establish a potential therapeutic approach for serrated-MSS CRCs whereby the amounts of aPKCs could be used as a biomarker for segregating these patients. This would address one of the major clinical obstacles regarding serrated CRC: the detection of the precursor lesions (IJspeert et al., 2015) . SSA/Ps are often flat and are frequently located in the proximal region (right side) of the colon, which makes it difficult to detect them with the current screening methods until they have progressed to an advanced stage. At the same time, these lesions have a higher risk of developing into CRC and are particularly aggressive. Indeed, the primary tumor location was an independent prognostic factor in a multivariate analysis that included consensus molecular signature, microsatellite status, and BRAF and KRAS status (Lee et al., 2017) . Right-sided CRC demonstrated a worse overall survival than left-sided CRC independently of the MSI and KRAS or BRAF mutation status (Lee et al., 2017) . Our study provides key insights into the development of serrated CRC that occurs in the proximal region and offers an animal model that closely mimics the human disease, which is likely to help improve the understanding of this type of CRC. Our data also revealed a potential association between IBD and serrated tumorigenesis because samples from patients with IBD were enriched with genes associated with serrated adenoma signatures, suggesting that these patients are at risk of developing this type of tumor. Moreover, we found that both aPKCs were reduced in this same cohort of IBD patients. Altogether, our results indicate that IBD patients could benefit from increased screening for SSA/Ps and that analysis of the amounts of aPKCs at initial IBD diagnosis could serve as a potential biomarker for those individuals who are at higher risk of developing serrated CRC. Our work suggests new avenues for the treatment of patients with IBD. Given our finding that broad-spectrum antibiotics could prevent the inflammation-driven induction of serrated tumorigenesis in Prkci fl/fl Prkcz fl/fl Villin-cre mice, we propose that control of the microbial flora could help in preventing the development of serrated CRCs in IBD patients.
In summary, the results of our study have implications for understanding the processes involved in the initiation of serrated adenomas and cancers, including in the absence of KRAS or BRAF mutations, and provide insight into avenues for the detection and treatment of this poor-prognosis subtype of CRC.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Table S1 FAM-labeled forward primers and reverse primers for MSI analysis 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice Prkcz fl/fl , Prkci fl/fl , Apc fl/fl , Villin-cre and Lgr5-EGFP-ires-creERT2 (Lgr5-creERT2) mice were previously described (Llado et al., 2015; Nakanishi et al., 2016) . For CD8 + T cell mediated cytotoxicity assay, OT-I TCR Tg (OT-I) mice (Jackson Laboratory) were used between 8 and 12 weeks of age. All mouse strains were generated in a C57BL/6 background, and were born and maintained under pathogen-free conditions. Mice were sacrificed, and small intestines and colons were collected for analyses. Animal handling and experimental procedures conformed to institutional guidelines and were approved by the SBP Medical Discovery Institute Institutional Animal Care and Use Committee. All genotyping was done by PCR. Age-and sex-matched mice were used for all experiments. For antibiotic treatment, 10-week-old Prkci fl/fl Prkcz fl/fl Villin-cre or Prkci fl/fl Villin-cre mice were administered a combination of ampicillin (1 g/l), neomycin (1 g/l), metronidazole (1 g/l), and vancomycin (0.5 g/l) in drinking water for 6 or 4 weeks, respectively, until they were sacrificed. For CD8 + T cell depletion, 10-week-old Prkci fl/fl Villin-cre mice were injected intraperitoneally with 200 mg of anti-CD8 antibody (clone 2.43) or control IgG twice a week for 5 weeks until they were sacrificed. For the TGF-bR1-specific inhibition experiment, 10-week-old Prkci fl/fl Prkcz fl/fl Villin-cre mice were treated twice a day with a dose of 10 mg of galunisertib (Tauriello et al., 2018) per os for 6 weeks until they were sacrificed. Control mice were treated with vehicle. For checkpoint immunotherapy, either 10-week-old or 13-week-old Prkci fl/fl Prkcz fl/fl Villin-cre mice were injected intraperitoneally with a dose of 10 mg/kg (body mass) of anti-PD-L1 antibody (clone 6E11) twice a week for 3 weeks until they were sacrificed. For the combination therapy of anti-PD-L1 antibody and TGF-bR1-specific inhibitor, 23-week-old Prkci fl/fl Prkcz fl/fl Villin-cre mice were treated twice a day with a dose of 10 mg of galunisertib per os and injected intraperitoneally with a dose of 10 mg/kg (body mass) of anti-PD-L1 antibody twice a week for 3 weeks until they were sacrificed. Anti-PD-L1 antibody was provided by de Sauvage FJ (Genentech).
Human samples
We obtained paraffin-embedded tissue sections from samples obtained from 107 patients during colonoscopy or surgery. Normal healthy colon samples (male, n = 8, average age at diagnosis = 56, age range 23-88; female, n = 9, average at diagnosis = 58, age range 29-81). Proximal colon cancer samples (male, n = 7, average age at diagnosis = 73, age range 39-91; female, n = 18, average at diagnosis = 73, age range 45-91). SSA/Ps samples (male, n = 13, average age at diagnosis = 61, age range 50-72; female, n = 10, average at diagnosis = 59, age range 46-75). Tubular adenoma samples (male, n = 15, average age at diagnosis = 65, age range 39-83; female, n = 6, average at diagnosis = 53, age range 50-59). Written informed consent was obtained from all patients with the protocol approved by the Ethics Committee of Scripps Green Hospital. De-identified samples were sent to SBP Medical Discovery Institute and used for histological analyses. The study was approved by the IRB Committee of SBP Medical Discovery Institute.
Cell lines
293T cell line (sex: female) was obtained directly from ATCC. MODE-K cells (sex: female) and MC38 OVA cells (sex: female) were kindly provided by Prof. Blumberg (Harvard Medical School, Boston, USA) and Prof. Fuchs (University of Pennsylvania, Philadelphia, USA) respectively. MC38 cell line (sex: female) was purchased from Kerafast. All cells were negative for mycoplasm.
METHOD DETAILS
Cell culture experiments MODE-K cells, 293T and MC38 OVA cells were cultured in DMEM (Cellgro, #15-017-CV) supplemented with 10% FBS, 2 mM of Glutamine and 100 U/ml penicillin and 100 mg/ml streptomycin, in an atmosphere of 95% air and 5% CO2. 293T sgPKCl/i were described previously (Nakanishi et al., 2016) . For ATP measurement and immunogenic cell death western blots, cells were treated with Oxaliplatin (20 mM), Bortezomib (0.1 mm) or 10 ng/ml of TNFa (Sigma) and 2.5 mg/ml of CHX (Sigma) for 24 hr. Extracellular ATP levels were measured by the luciferin-based ATPlite Assay (Perkin Elmer) using Varioskan Lux reader (Thermo Fisher, as indicated by the manufacturer. For poly(I:C) treatment, cells were transfected with 0.5 ug/ml of poly(I:C) (InVivoGen) using Lipofectamine 2000 (Invitrogen). Cells for protein analysis were lysed in RIPA buffer (20 mM Tris-HCl, 37 mM NaCl, 2 mM EDTA, 1% Triton-X, 10% glycerol, 0.1% SDS, and 0.5% sodium deoxycholate), with phosphatase and protease inhibitors. Cell extracts were denatured, subjected to SDS-PAGE, transferred to PVDF membranes (GE Healthcare), and immunoblotted with the specific antibodies as listed in STAR methods Reagents table. To knock down PKCz in 293T sgPKCl/i cells and PKCl/i in MC38 OVA cells, TRC lentiviral shRNA targeting human PKCz (TRCN0000001219) and TRC shRNA targeting mouse PKCl/i (TRCN000022757) were obtained from Open Biosystems. shRNA-encoding plasmids were co-transfected with psPAX2 (Addgene plasmid #12260; a gift from Dr. Didier Trono) and pMD2.G (Addgene plasmid #12259; a gift from Dr. Didier Trono) packaging plasmids into actively growing 293T cells by using XtremeGene HP transfection reagent (Roche). Virus-containing supernatants were collected 48 hr after transfection, filtered to eliminate cells, and then used to infect the target cells in the presence of 8 mg/ml polybrene (Millipore). Cells were analyzed after puromycin selection (1 mg/ml) to confirm knockdown. To knock out PKCz in 293T sgPKCl/i cells, lentiviral guide RNA plasmid targeting human PKCz (BRDN0001149519) and lentiviral vector expressing Cas9 and blasticidin resistance were obtained from Addgene. Cells were treated virus-containing supernatants and selected with puromycin and blasticidin. Colonies from single cell were expanded and screened for PKCz by immunoblotting. To knock out PKCl/i in MODE-K cells, a 20-nucleotide single-guide RNA (sgRNA) sequence targeting mouse PKCl/i was designed using the CRISPR design tool at http://crispr.mit.edu/. The sgRNA was cloned in the lentiCRISPR v2 vector (a gift from Feng Zhang) and transduced into MODE-K cells. Cells were selected with puromycin and colonies from single cell were expanded and screened for PKCl/i by immunoblotting.
Histology, immunohistochemistry, immunofluorescence, and in situ hybridization Organs were isolated, rinsed in ice-cold PBS, fixed in 10% neutral buffered formalin overnight at 4 C, dehydrated, and embedded in paraffin. Sections (5 mm) were stained with hematoxylin and eosin (H&E). For immunohistochemistry, sections were deparaffinized, rehydrated, and then treated for antigen retrieval. After blocking in Protein Block Serum-Free solutions (DAKO), tissues were incubated with primary antibody overnight at 4 C followed by incubation with biotinylated secondary antibody. Endogenous peroxidase was quenched in 3% H2O2 in water for 10 min at room temperature. Antibodies were visualized with avidin-biotin complex (Vectastain Elite; Vector Laboratories) using diaminobenzidine as the chromagen. For immunofluorescence, fresh frozen organs were embedded in Tissue-Tek OCT compound (Sakura) and section of 10 mm were fixed in methanol, washed with PBS and then incubated with the primary antibodies. Washed sections were incubated with Alexa-conjugated secondary antibodies (Life Technologies) and examined with a Zeiss LSM 710 NLO Confocal Microscope. In situ hybridization for murine Ereg was carried out using RNAscope Multiplex Fluorescent Assay kit (Advanced Cell Diagnostics) following manufacturer's instructions. The probe corresponding to CDS region of murine Ereg (GenBank: NM_007950.2, probe region: 116-1496; Advanced Cell Diagnostics; Cat#: 437981). Cell death was analyzed using the In Situ Cell Death Detection kit, TMR red (Thermo) for TUNEL. Masson's Trichrome staining was carried out following manufacturer's instructions (Sigma HT15-1KT).
Flow cytometry analysis
Flow cytometry experiments were performed using fresh small intestinal tissue and organoid preparations. For the analyses of small intestinal tissue, a half part of duodenum, jejunum, and ileum was used for quantitative flow cytometry analysis of immune cell population of lamina propria. Briefly, small intestines were rinsed in cold PBS, minced into small pieces, incubated in HBSS with EDTA (5 mM) and digested with collagenase (0.05 mg/ml) for 30 min at 37 C, followed by a discontinuous Percoll separation method (40 and 75%) to purify immune cells. The cells concentrated at the interface were collected and washed in cold PBS. Red blood cells were removed with lysing buffer (BD Pharm Lyse) and live cells were counted using Trypan blue and then saturated with mouse Fc Block (purified anti-mouse CD16;CD32; 1:50; clone 2.4G2; BD PharMingen) 30 min at 4 C before incubating with specific dyed antibodies. For IL-17A intracellular staining, cells were pretreated with 50 ng/ml of phorbolmyristate acetate and 500 ng/ml of ionomycin in the presence of 10 mg/ml of brefeldin A for 3 hr at 37 C 5% CO2. Cells were then stained with specific extracellular antibodies, permeabilized with Fixation/Permeabilization solution kit (BD Cytofix-Cytoperm) according to manufacturer's instructions and finally incubated with anti-IL-17A (clone TC11-18H10; BD PharMingen) specific antibody in Perm-Wash buffer overnight at 4 C. For FOXP3 intracellular staining, cells were stained with specific extracellular antibodies, permeabilized with the same BD Cytofix-Cytoperm kit and finally stained with anti-FOXP3 (clone FJK-16 s) specific antibody in Perm-Wash buffer overnight at 4 C. For generation of small intestine organoids, organoids were collected in ice-cold TrypLE solution (Life Technologies) to remove Matrigel, then pipetted 5 cycles and incubated 5 min at 37
C to obtain single-cell suspension. Cells were washed twice in PBS 3% FBS and resuspended at room temperature with PBS with 100 mg/ml DNase I for 10 min before staining with anti-H-2Kb (clone AF6-88.5.5.3; eBioscience). For antigen presentation in MODE-K cells, cells were washed in PBS, trypsinized and wash with warm medium. Then, cells were resuspended and stained with anti-H-2Kk (clone 36-7-5; BioLegend) and anti-H-2Dk (clone 15-5-5; BD PharMingen). Dead cells were excluded after 7-AAD staining. All flow cytometry experiments were performed on a BD LSRFortessa 14-colors analyzer at the Sanford Burnham Prebys Medical Discovery Institute Shared FACS Facility and flow cytometry data were analyzed using FlowJo software (Tree Star Inc.).
For T cell killing assay of MC38 OVA cells, CD8 + T cells were isolated from the spleen of OT-I mice by magnetic sorting using EasySep Mouse CD8 + T Cell Isolation Kit (StemCell Technologies, Inc.) according to the manufacturer's instructions. To generate effector cells, naive T cells were cultured at 106/mL for 3 days with immobilized anti-CD3 (10 mg/mL) and soluble anti-CD28 (5 mg/mL) (Bio X Cell). After 3 days, effector CD8 + T cells were co-cultured with 1x104 OVA -expressing MC38 target cells (shNT and shl/i) or MC38 target cells at different ratios (2:1; 1:1; 1:2; 1:10; 1:20; 1:50) for 24 hr at 37 C, 5% CO2. MC38 cell line was used as a negative control. The supernatants were harvested and analyzed using a Pierce LDH Cytotoxicity Assay Kit (Thermo Scientific) to determine the specific cytotoxicity according to the manufacturer's instructions. For the PI staining, 100 mM propidium iodide was added to the culture medium when the OT-I cells were added. PI signal was measured 24 hr after coculture with OT-I cells using a Varioskan LUX multimode microplate reader (ThermoFisher Scientific).
Intestinal epithelial cell isolation and small intestinal organoid culture Intestinal epithelial cell (IEC) isolation was performed as described previously with some modification (Llado et al., 2015) . Briefly, small intestines were removed, washed with cold PBS without magnesium chloride and calcium (PBS À/À ) opened longitudinally, cut into 5 mm fragments, and then washed several times with cold PBS À/À until clean. Cut tissue fragments were incubated with PBS À/À EDTA (5 mM) containing 10% FBS for 40-60 min at 4 C. IECs were then mechanically separated from the connective tissue by rigorous shaking, and then filtered through a 100-mm mesh into a 50 mL conical tube to remove tissue fragments. Isolated IECs were pelleted and then lysed for RNA or protein extraction. For small intestine organoid culture, we collected small intestinal adenoma tissues from Lgr5-creERT2;Apc fl/fl (WT) or Lgr5-creERT2;Apc fl/fl ;Prkcz fl/fl (Prkcz À/À ) mice injected with tamoxifen (sigma) intraperitoneally. Isolated adenoma tissues were minced into small pieces and incubated in digestion buffer (Dulbecco's modified Eagle medium with 10% FBS, penicillin-streptomycin, 1 mg/ml collagenase type Xl, 0.1 mg/ml DNase l, 10 mM Y-27632) for 15-20 min at 37 C. The digested adenoma fragments were washed with PBS À/À and then filtered through a 100-mm mesh into a 50 mL conical tube to remove stromal fragments. Adenoma fragments were counted after isolation and a total of 250-500 fragments were mixed with 100 mL of growth factor reduced-Matrigel and plated in 12-or 24-well plates. After polymerization of Matrigel, 1 mL of culture medium (Advanced DMEM-F12 containing 10 mM HEPES, 1X Glutamax, 1X B27 supplement, 50 ng/ml EGF and 10 mM Y-27632) was added. For experiment to examine the interferon response, organoids were treated with 3 mM of 5-AZA-CdR (Sigma). After 24 hr incubation, the medium was replaced with fresh drug-free medium, and then organoids were cultured for an additional 3 days for RNA or flow cytometry analyses.
MSI Analysis
For examination of microsatellite instability (MSI) five microsatellite repeat markers (Bennecke et al., 2010; Rad et al., 2013) were amplified by PCR using DNA isolated from WT and Prkci fl/fl Prkcz fl/fl Villin-cre mouse tissues. 10 ng of DNA was amplified with FAM-labeled forward primers and reverse primers (see Table S2 ) specific for the previously validated murine microsatellite markers Bat24, Bat26, Bat30, Bat37, Bat64. Hi-Di and LIZ size standard were added to the samples and separation and detection of amplified fragments was performed on the 3730xl DNA Analyzer (Eton Bioscience). Data were analyzed with Peak ScannerTM Software from Applied Biosystems to identify the allelic patterns for each marker. Allelic patterns for normal and tumor tissues were compared and scored based on the size of the predominant allele and the presence of allelic variants. Tumor samples with greater or equal 40% MSI were classified as MSI-high (MSI-H), less than 40% as MSI-low (MSI-L), and samples without alterations were classified as microsatellite stable (MSS).
RNA extraction and analysis
Total RNA from mouse tissues and cultured organoids was extracted using the TRIZOL reagent (Invitrogen) and the RNeasy Mini Kit (QIAGEN), followed by DNase treatment. After quantification using a Nanodrop 1000 spectrophotometer (Thermo Scientific), RNA was either processed for RNA-seq or reverse-transcribed using random primers and MultiScribe Reverse Transcriptase (Applied Biosystems). Gene expression was analyzed by amplifying 20 ng of the complementary DNA using the CFX96 Real Time PCR Detection System with SYBR Green Master Mix (BioRad) and primers described in Table S1 . The amplification parameters were set at 95 C for 30 s, 58 C for 30 s, and 72 C for 30 s (40 cycles total). Gene expression values for each sample were normalized to the 18S RNA. Each sample was extracted from independent mice. RNA-seq studies were performed in the Genomics Core at SBP Medical Discovery Institute. Briefly, poly(A) RNA was isolated using the NEBNextÒ Poly(A) mRNA Magnetic Isolation Module and barcoded libraries were made using the NEBNextÒ Ultra Directional RNA Library Prep Kit for IlluminaÒ (NEB, Ipswich MA). Libraries were pooled and single end sequenced (1X75) on the Illumina NextSeq 500 using the High output V2 kit (Illumina). Sequencing Fastq files were uploaded to BaseSpace and processed with RNAexpress App (Illumina) to obtain raw reads counts for each gene. The gene matrix files were generated with RNAexpress App and compared using t test comparison and log2 ratio of classes.
class 1, size = 96; ''FUJII_CLASS2_ SERRATED_UP'' = upregulated genes in class 2, size = 130; ''FUJII_CLASS4_ ADENOMA_DOWN'' = downregulated genes in class 4, size = 223) (Fujii et al., 2016) . The ''DELKER_SERRATED_UP'' signature was generated based on a list of top 50 gene transcripts increased by RNA-seq in SSA/Ps in serrated polyposis patients compared to controls (Delker et al., 2014) . The ''Prkci fl/fl Prkcz fl/fl Villin-cre_SIGNATURE'' (size = 358) was generated based on a list of gene transcripts significantly increased by RNA-seq in Prkci fl/fl Prkcz fl/fl Villin-cre IECs compared to WT IECs (logFC > 1, FDR < 0.01, Table S3 ).
Classification of CRC samples into CCS1 to CCS3 was performed by K_means_clustering using Morpheus (https://software. broadinstitute.org/morpheus/) with applying the CCS classifier to each dataset (De Sousa E. Melo et al., 2013) .
Survival analyses CRC patient samples (GEO: GSE5851, GSE33113, TCGA) were segregated into four subgroups: PRKCI Low PRKCZ
